Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Why the study?
Does colchicine 0.5 mg daily reduce ischemic cardiovascular events in patients with a recent myocardial infarction?
Key Points
- This study aims to assess the efficacy and safety of low-dose colchicine after myocardial infarction.
- Randomized, placebo-controlled trial with patients having a recent myocardial infarction.
- Intervention involved administering colchicine at a dose of 0.5 mg daily compared to placebo.
- ClinicalTrials.gov number NCT02551094 registered.
- Patients receiving colchicine demonstrated a significantly lower risk of ischemic cardiovascular events compared to those on placebo.
Structured PICO
Does colchicine 0.5 mg daily reduce ischemic cardiovascular events in patients with a recent myocardial infarction?
P
Population
Patients with a recent myocardial infarction
I
Intervention
Colchicine 0.5 mg daily
C
Comparator
Placebo
O
Outcome
Ischemic cardiovascular eventshard clinical
Low-dose colchicine (0.5 mg daily) significantly reduces the risk of ischemic cardiovascular events following a recent myocardial infarction.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
JTJean-Claude TardifProfessor of medicine, University of Montreal
“In addition to standard of care in patients with a recent MI, colchicine 0.5 mg daily significantly reduces the risk for first ischemic CV events by 23% and total ischemic cardiovascular events by 34%.”
“This will be a landmark study.”
“Having a safe drug that's easily available; it will be hard to hold this one back. What the guidelines will need to wrestle with is there are five drugs already recommended to use after an MI; is colchicine number six?”
Implication
Supports low-dose colchicine after recent MI; reinforces prior trial evidence for ischemic event reduction.
Abstract
Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo. (Funded by the Government of Quebec and others; COLCOT ClinicalTrials.gov number, NCT02551094.).
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Tardif et al. (2019) studied this question.